Global Hormone Replacement Therapy Market 2014-2018

ホルモン補充療法(HRT)のグローバル市場(2014-2018)

◆タイトル:Global Hormone Replacement Therapy Market 2014-2018
◆商品コード:IRTNTR3762
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年7月7日
◆ページ数:87
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥310,800見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"ホルモン補充療法(HRT)のグローバル市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、種類別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Hormone Replacement Therapy
Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer’s disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer.
TechNavio’s analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018.
Covered in this Report
The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. This report covers the present scenario and the growth prospects of the Global Hormone Replacement Therapy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of the various hormone replacement therapies that are available in the market.
TechNavio’s report, the Global Hormone Replacement Therapy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Hormone Replacement Therapy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Actavis plc
• Bayer AG
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk A/S
Other Prominent Vendors

• Abbott Laboratories Ltd.
• Amgen Inc.
• ANI Pharmaceuticals Inc.
• Hisamitsu Pharmaceutical Co. Inc.
• Mylan Laboratories Inc.
• Orion Corp.
• QuatRx Pharmaceuticals Co.
• Teva Pharmaceutical Industries Ltd.
• TherapeuticsMD Inc.
Key Market Driver
• Significant Unmet Need for Hormone Replacement Therapy
• For a full, detailed list, view our report.
Key Market Challenge
• High Cost of Hormone Replacement Therapy
• For a full, detailed list, view our report.
Key Market Trend
• Paradigm Shift Toward Transdermal Systems
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Type of Therapy
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 Actavis plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Business Segmentation
17.1.4 Business Segmentation by Revenue 2012 and 2013
17.1.5 Sales by Geography
17.1.6 Business Strategy
17.1.7 Key Information
17.1.8 SWOT Analysis
17.1.9 Strengths
17.1.10 Weaknesses
17.1.11 Opportunities
17.1.12 Threats
17.2 Bayer AG
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation
17.2.4 Business Strategy
17.2.5 Sales Segmentation by Business
17.2.6 Sales by Geographical Segmentation
17.2.7 Key Information
17.2.8 SWOT Analysis
17.2.9 Strengths
17.2.10 Weaknesses
17.2.11 Opportunities
17.2.12 Threats
17.3 Merck & Co. Inc.
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Business Segmentation by Revenue 2013
17.3.4 Business Segmentation by Revenue 2012 and 2013
17.3.5 Sales by Geography
17.3.6 Business Strategy
17.3.7 Key Developments
17.3.8 SWOT Analysis
17.3.9 Strengths
17.3.10 Weaknesses
17.3.11 Opportunities
17.3.12 Threats
17.4 Novartis AG
17.4.1 Key Facts
17.4.2 Business Overview
17.4.3 Business Segmentation by Revenue 2013
17.4.4 Business Segmentation by Revenue 2012 and 2013
17.4.5 Sales by Geography
17.4.6 Business Strategy
17.4.7 Key Developments
17.4.8 SWOT Analysis
17.4.9 Strengths
17.4.10 Weaknesses
17.4.11 Opportunities
17.4.12 Threats
17.5 Novo Nordisk A/S
17.5.1 Key Facts
17.5.2 Business Overview
17.5.3 Business Segmentation by Revenue 2013
17.5.4 Business Segmentation by Revenue 2012 and 2013
17.5.5 Sales by Geography
17.5.6 Business Strategy
17.5.7 Key Information
17.5.8 SWOT Analysis
17.5.9 Strengths
17.5.10 Weakness
17.5.11 Opportunities
17.5.12 Threats
17.6 Pfizer Inc.
17.6.1 Key Facts
17.6.2 Business Overview
17.6.3 Business Segmentation by Revenue 2013
17.6.4 Business Segmentation by Revenue 2012 and 2013
17.6.5 Sales by Geography
17.6.6 Business Strategy
17.6.7 Key Developments
17.6.8 SWOT Analysis
17.6.9 Strengths
17.6.10 Weaknesses
17.6.11 Opportunities
17.6.12 Threats
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hormone Replacement Therapy Market 2013-2018 (US$ billion)
Exhibit 3: Global Hormone Replacement Therapy Market by Type of Therapy
Exhibit 5: Global Hormone Replacement Therapy Market by Geographical Segmentation 2013
Exhibit 6: Global Hormone Replacement Therapy marketBusiness Segmentation 2013
Exhibit 7: Global Hormone Replacement Therapy market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 8: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 9: Business Segmentation of Bayer AG 2013
Exhibit 10: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 11: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 15: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 16: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 17: Novartis AG: Sales by Geography 2013
Exhibit 18: Novo Nordisk A/S: Business Segmentation by Revenue 2013
Exhibit 19: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 21: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: Pfizer Inc.: Sales by Geography 2013



【掲載企業】

Actavis plc , Bayer AG , Merck & Co. Inc., Novartis AG , Novo Nordisk A/S , Abbott Laboratories Ltd., Amgen Inc., ANI Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., MylanLaboratories Inc., Orion Corp., QuatRx Pharmaceuticals Co., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc.

【資料のキーワード】

ホルモン補充療法、ホルモン療法、月経閉止期

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ホルモン補充療法(HRT)のグローバル市場(2014-2018)] (Global Hormone Replacement Therapy Market 2014-2018 / IRTNTR3762)販売に関する免責事項
[ホルモン補充療法(HRT)のグローバル市場(2014-2018)] (Global Hormone Replacement Therapy Market 2014-2018 / IRTNTR3762)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆